Design, Synthesis, and Evaluation of Lung-Retentive Prodrugs for Extending the Lung Tissue Retention of Inhaled Drugs

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2022 Jul 7

PMID 35798565

Authors

Jack Ayre

Joanna M Redmond

Giovanni Vitulli

Laura Tomlinson

Richard Weaver

Eleonora Comeo

Cynthia Bosquillon

Michael J Stocks

Affiliations

Soon will be listed here.

Abstract

A major limitation of pulmonary delivery is that drugs can exhibit suboptimal pharmacokinetic profiles resulting from rapid elimination from the pulmonary tissue. This can lead to systemic side effects and a short duration of action. A series of dibasic dipeptides attached to the poorly lung-retentive muscarinic M3 receptor antagonist piperidin-4-yl 2-hydroxy-2,2-diphenylacetate () through a pH-sensitive-linking group have been evaluated. Extensive optimization resulted in 1-((()-2-(()-2,6-diaminohexanamido)-3,3-dimethylbutanoyl)oxy)ethyl 4-(2-hydroxy-2,2-diphenylacetoxy)piperidine-1-carboxylate (), which combined very good stability and very high rat lung binding. Compound progressed to pharmacokinetic studies in rats, where, at 24 h post dosing in the rat lung, the total lung concentration of was 31.2 μM. In addition, high levels of liberated drug were still detected locally, demonstrating the benefit of this novel prodrug approach for increasing the apparent pharmacokinetic half-life of drugs in the lungs following pulmonary dosing.

References

Garces A, Al-Hayali M, Lee J, Li J, Gershkovich P, Bradshaw T . Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. ACS Med Chem Lett. 2020; 11(3):316-321. PMC: 7073869. DOI: 10.1021/acsmedchemlett.9b00378. View

Chen X, Huang W, Wong B, Yin L, Wong Y, Xu M . Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine. 2012; 7:1139-48. PMC: 3299201. DOI: 10.2147/IJN.S28011. View

Xu R, Sim M, Go M . Synthesis, antimuscarinic activity and quantitative structure-activity relationship (QSAR) of tropinyl and piperidinyl esters. Chem Pharm Bull (Tokyo). 1998; 46(2):231-41. DOI: 10.1248/cpb.46.231. View

Connolly S, Alcaraz L, Bailey A, Cadogan E, Christie J, Cook A . Design-driven LO: the discovery of new ultra long acting dibasic β2-adrenoceptor agonists. Bioorg Med Chem Lett. 2011; 21(15):4612-6. DOI: 10.1016/j.bmcl.2011.05.097. View

Anderson G, Linden A, Rabe K . Why are long-acting beta-adrenoceptor agonists long-acting?. Eur Respir J. 1994; 7(3):569-78. DOI: 10.1183/09031936.94.07030569. View

Bayard F, Thielemans W, Pritchard D, Paine S, Young S, Backman P . Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung. J Control Release. 2013; 171(2):234-40. DOI: 10.1016/j.jconrel.2013.07.023. View

Cooper A, Ferguson D, Grime K . Optimisation of DMPK by the inhaled route: challenges and approaches. Curr Drug Metab. 2012; 13(4):457-73. DOI: 10.2174/138920012800166571. View

Rosiere R, Berghmans T, De Vuyst P, Amighi K, Wauthoz N . The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses. Cancers (Basel). 2019; 11(3). PMC: 6468657. DOI: 10.3390/cancers11030329. View

Brillault J, Tewes F . Control of the Lung Residence Time of Highly Permeable Molecules after Nebulization: Example of the Fluoroquinolones. Pharmaceutics. 2020; 12(4). PMC: 7238242. DOI: 10.3390/pharmaceutics12040387. View

10.

Alcaraz L, Bailey A, Cadogan E, Connolly S, Jewell R, Jordan S . From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonists. Bioorg Med Chem Lett. 2011; 22(1):689-95. DOI: 10.1016/j.bmcl.2011.10.049. View

11.

Rytting E, Bur M, Cartier R, Bouyssou T, Wang X, Kruger M . In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles. J Control Release. 2009; 141(1):101-7. DOI: 10.1016/j.jconrel.2009.08.021. View

12.

Campa C, Silva R, Margaria J, Pirali T, Mattos M, Kraemer L . Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis. Nat Commun. 2018; 9(1):5232. PMC: 6290777. DOI: 10.1038/s41467-018-07698-6. View

13.

Jones L, Burrows J, Feeder N, Glossop P, James K, Jones R . Molecular hybridization yields triazole bronchodilators for the treatment of COPD. Bioorg Med Chem Lett. 2015; 25(22):5121-6. DOI: 10.1016/j.bmcl.2015.10.008. View

14.

Perry M, Bjorhall K, Bonn B, Carlsson J, Chen Y, Eriksson A . Design and Synthesis of Soluble and Cell-Permeable PI3Kδ Inhibitors for Long-Acting Inhaled Administration. J Med Chem. 2017; 60(12):5057-5071. DOI: 10.1021/acs.jmedchem.7b00401. View

15.

Tejani-Butt S, Luthin G, Wolfe B, Brunswick D . N-substituted derivatives of 4-piperidinyl benzilate: affinities for brain muscarinic acetylcholine receptors. Life Sci. 1990; 47(10):841-8. DOI: 10.1016/0024-3205(90)90596-j. View

16.

Toniolo C, Crisma M, Formaggio F, Peggion C . Control of peptide conformation by the Thorpe-Ingold effect (C alpha-tetrasubstitution). Biopolymers. 2002; 60(6):396-419. DOI: 10.1002/1097-0282(2001)60:6<396::AID-BIP10184>3.0.CO;2-7. View

17.

Patton J, Byron P . Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2006; 6(1):67-74. DOI: 10.1038/nrd2153. View

18.

Maselli D, Keyt H, Restrepo M . Inhaled Antibiotic Therapy in Chronic Respiratory Diseases. Int J Mol Sci. 2017; 18(5). PMC: 5454974. DOI: 10.3390/ijms18051062. View

19.

Oh Y, Lee J, Seo J, Rhim T, Kim S, Yoon H . Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model. J Control Release. 2010; 150(1):56-62. DOI: 10.1016/j.jconrel.2010.11.001. View

20.

Drozdzik M, Drozdzik M, Oswald S . Membrane Carriers and Transporters in Kidney Physiology and Disease. Biomedicines. 2021; 9(4). PMC: 8070919. DOI: 10.3390/biomedicines9040426. View